MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-19-2026
Taysha Gene Therapies Cash Conversion Cycle 2011-2026 | TSHA
Annual Cash Conversion Cycle Taysha Gene Therapies
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -37.8 | -50 | -119 | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -37.8 | -119 | -69 |
Quarterly Cash Conversion Cycle Taysha Gene Therapies
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -54 | -50.6 | -32 | - | -67.1 | -95.3 | -92.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -32 | -95.3 | -65.2 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
117 | - | -24.86 % | $ 820 K |  USA |
 |
Amgen
AMGN
|
217 | $ 345.82 | 1.71 % | $ 186 B | USA |
 |
Amneal Pharmaceuticals
AMRX
|
117 | $ 12.61 | 2.35 % | $ 3.95 B | USA |
 |
I-Mab
IMAB
|
-1.97 K | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
Arcutis Biotherapeutics
ARQT
|
158 | $ 24.35 | 4.64 % | $ 3.1 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-2.15 K | - | - | $ 7.46 M |  Israel |
 |
AstraZeneca PLC
AZN
|
-58 | - | - | $ 96.9 B |  Britain |
 |
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
119 | $ 1.44 | 5.51 % | $ 383 M | Britain |
 |
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Advaxis
ADXS
|
-143 K | - | -9.65 % | $ 45.9 M | USA |
 |
Aytu BioScience
AYTU
|
174 | $ 2.74 | 6.42 % | $ 17.2 M | USA |
 |
Avid Bioservices
CDMO
|
85.5 | - | - | $ 789 M | USA |
 |
Cidara Therapeutics
CDTX
|
2.26 K | - | - | $ 1.41 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
Cerus Corporation
CERS
|
47 | $ 1.94 | 5.43 % | $ 370 M | USA |
 |
CTI BioPharma Corp.
CTIC
|
-216 | - | - | $ 1.2 B | USA |
 |
AIkido Pharma
AIKI
|
-1.92 | - | 1.93 % | $ 17.4 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-1.6 K | - | -4.36 % | $ 27 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-101 | - | - | $ 2.18 B | USA |
 |
Dynavax Technologies Corporation
DVAX
|
459 | - | - | $ 2.02 B | USA |
 |
Coherus BioSciences
CHRS
|
149 | $ 1.68 | 0.6 % | $ 197 M | USA |